Wuhan Hiteck Biological Pharma Co.,Ltd
SZSE:300683.SZ
46.4 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 602.284 | 688.626 | 614.683 | 524.123 | 620.163 | 590.873 | 750.259 | 770.974 | 679.407 | 548.791 | 355.993 |
| Cost of Revenue
| 345.055 | 354.882 | 264.791 | 214.083 | 120.259 | 44.211 | 35.157 | 35.591 | 32.996 | 27.108 | 18.748 |
| Gross Profit
| 257.229 | 333.744 | 349.893 | 310.041 | 499.905 | 546.662 | 715.102 | 735.383 | 646.411 | 521.684 | 337.244 |
| Gross Profit Ratio
| 0.427 | 0.485 | 0.569 | 0.592 | 0.806 | 0.925 | 0.953 | 0.954 | 0.951 | 0.951 | 0.947 |
| Reseach & Development Expenses
| 128.903 | 121.434 | 103.166 | 86.121 | 62.65 | 29.857 | 24.498 | 30.035 | 25.046 | 16.851 | 10.66 |
| General & Administrative Expenses
| 36.443 | 31.993 | 41.964 | 41.012 | 26.27 | 17.398 | 12.155 | 10.114 | 11.839 | 5.976 | 20.563 |
| Selling & Marketing Expenses
| 128.665 | 126.705 | 145.665 | 151.791 | 311.072 | 365.666 | 495.874 | 508.574 | 443.876 | 362.351 | 218.86 |
| SG&A
| 165.107 | 158.698 | 187.628 | 192.803 | 337.342 | 383.065 | 508.029 | 518.688 | 455.716 | 368.327 | 239.423 |
| Other Expenses
| -8.913 | -1.001 | -0.884 | -14.026 | -10.762 | -0.192 | 9.386 | 2.2 | 2.738 | -0.178 | 0.918 |
| Operating Expenses
| 363.569 | 338.429 | 341.467 | 326.247 | 445.39 | 429.988 | 544.369 | 560.535 | 492.274 | 395.746 | 242.467 |
| Operating Income
| -143.073 | -6.823 | 21.34 | -35.076 | 75.051 | 105.245 | 156.454 | 181.889 | 94.537 | 128.676 | 89.829 |
| Operating Income Ratio
| -0.238 | -0.01 | 0.035 | -0.067 | 0.121 | 0.178 | 0.209 | 0.236 | 0.139 | 0.234 | 0.252 |
| Total Other Income Expenses Net
| -8.913 | -1.001 | -0.884 | -2.293 | -2.44 | -0.192 | 9.386 | 2.194 | 2.731 | -0.189 | 0.879 |
| Income Before Tax
| -151.986 | -7.824 | 20.456 | -37.368 | 72.611 | 105.053 | 165.84 | 184.084 | 97.268 | 128.487 | 90.708 |
| Income Before Tax Ratio
| -0.252 | -0.011 | 0.033 | -0.071 | 0.117 | 0.178 | 0.221 | 0.239 | 0.143 | 0.234 | 0.255 |
| Income Tax Expense
| -23.743 | 0.074 | -9.559 | -11.694 | 11.424 | 13.589 | 24.643 | 27.348 | 14.038 | 19.519 | 13.113 |
| Net Income
| -120.823 | -14.03 | 27.654 | -25.026 | 63.035 | 94.138 | 142.39 | 157.053 | 83.347 | 109.912 | 77.654 |
| Net Income Ratio
| -0.201 | -0.02 | 0.045 | -0.048 | 0.102 | 0.159 | 0.19 | 0.204 | 0.123 | 0.2 | 0.218 |
| EPS
| -0.93 | -0.11 | 0.26 | -0.24 | 0.61 | 0.91 | 1.65 | 2.03 | 1.09 | 1.59 | 1.21 |
| EPS Diluted
| -0.93 | -0.11 | 0.26 | -0.24 | 0.61 | 0.91 | 1.65 | 2.03 | 1.09 | 1.59 | 1.21 |
| EBITDA
| -18.965 | 71.193 | 72.828 | 38.531 | 113.006 | 163.605 | 209.901 | 189.043 | 234.17 | 142.332 | 101.24 |
| EBITDA Ratio
| -0.031 | 0.103 | 0.118 | 0.074 | 0.182 | 0.277 | 0.28 | 0.245 | 0.345 | 0.259 | 0.284 |